Theme: New insights in diagnosis and management for hypertension

Hypertension 2017

Hypertension 2017

Conference series LLC is proud to host the 2nd International Conference on Hypertension & Healthcare during the beautiful month of Sep 11-13, 2017 at Amsterdam, Netherlands, the place which sees the largest influx of tourists in Amsterdam. Working under the theme “New insights in diagnosis and management for hypertension” we bring together the brightest and most productive minds to discuss the intricate concepts of Hypertension diagnosis and management.

The conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical professionals like Directors, Heads, Deans, Professors, Scientists, Researchers, Cardiologists and Writers of the Hypertension or Cardiology and related departments, Founders and Employees of the related companies, Associations, Organizations, Laboratory members and Young researchers working in the field of hypertension treatment and management. This conference mainly focuses on spreading the awareness about challenges in this field and how to prevent and manage hypertension. 

Conference Series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. Conference Series LLC organize 600+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend?? 

Encounter the target market with members from across the globe, committed to learn about hypertension treatment and management. This is the best opportunity to outreach the largest gathering of participants from around the world. Conduct presentations, distribute and update knowledge about the current situation of hypertension treatment and receive name recognition at this 3-day event. World-eminent speakers, most recent researches, latest treatment techniques and the advanced updates in Hypertension Treatment and Management are the principal features of this conference.        

Target Audience:

Our Organization would be privileged to welcome the:

  • Directors of Hypertension or related Programs or Associations
  • Heads, Deans and Professors of Hypertension or Cardiology and related departments
  • Scientists and Researchers
  • Doctors
  • Writers
  • Founders and Employees of the related companies
  • Hypertension Associations and Organizations
  • Laboratory members and Students working in the field of hypertension treatment and management

Encouraged with the success of Hypertension Conference Series, we bring up the 2nd International Conference on Hypertension & Healthcare.  With its powerful 3 day agenda Hypertension 2017 is designed to take place at the beautiful Netherlands in the Amsterdam City during Sep 11-13, 2017.

We focus on bringing together world’s most productive visionaries, professors, cardiologists and leading researchers to share their research works and results in the field of Hypertension. Take a deep dive into the newest technologies made in the field with the edifying talks of our Speakers which will help in broadening your horizons.

Hypertension-2017 is an international platform for presenting research about Hypertension and related concepts, sharing alternative ideas about the severe cardiovascular risk factor, thus contributing to the dissemination of information about the trouble for the welfare of the society. This event enables its patrons to showcase their research works in front of Speakers, Delegates and Attendees from vastly different areas across the Globe.

The conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical professionals like Directors, Heads, Deans, Professors, Scientists, Researchers, Cardiologists and Writers of the Hypertension or Cardiology and related departments, Founders and Employees of the related companies, Associations, Organizations, Laboratory members and Young researchers working in the field of hypertension treatment and management. This conference mainly focuses on spreading the awareness about challenges in this field and how to prevent and manage hypertension. 

Track 1: Hypertension

Hypertension, also known as high blood pressure or arterial hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated. This session mainly covers the different types of hypertension and their assessment. There are two primary hypertension types. For 95% of people with high blood pressure, the cause of their hypertension is unknown — this is called essential or primary hypertension. When a cause can be found, the condition is called secondary. Isolated systolic hypertensionmalignant hypertension, and resistant hypertension are all recognized hypertension types with specific diagnostic criteria.

Assessment of hypertension basically includes: Confirmation of hypertension, Risk factors, Underlying causes, End organ damage & Indications and contraindications for antihypertensive drugs.

Hypertension is a major risk factor for heart diseases and stroke. Globally, the overall prevalence of raised blood pressure in adults aged 25 and over was around 40% in 2008. Because of population growth and ageing, the number of people with uncontrolled hypertension rose from 600 million in 1980 to nearly 1 billion in 2008.The national Million Hearts initiative endeavours to increase the number of persons whose hypertension is under control, by 10 million, as part of its goal to prevent 1 million heart attacks and strokes by the year 2017. 

Related Conferences: 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA;  8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9thArrhythmia  Meeting, July 14-15 2016, Australia ; ASH Meeting  2016;  Ischemic Heart Diseases Conference, October 20-21, 2016  Chicago, USA; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; European Hypertension Congress 2016 ; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon;  British Hypertension Society 2016 ;  3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia

Track 2: Hypertension & Obesity

Hypertension (high blood pressure) refers to the pressure that blood applies to the inner walls of the arteries. Obesity increases the risk of the development of hypertension. The respective session mainly focuses on obesity-related hypertension, its interaction with the outcomes of hypertension, risk factors, treatment and management of obesity induced hypertension. 

Obesity-associated arterial hypertension is characterized by activation of the sympathetic nervous system, activation of the renin-angiotensin system, and sodium retention, among other abnormalities. It is estimated that excess body weight, accounted for approximately 26% of cases of hypertension in men and 28% in women and for approximately 23% of cases of coronary heart disease in men and 15% in women. Obese individuals have an increase in fatty tissue that increases their vascular resistance and in turn increases the work the heart has to do to pump blood throughout the body. Indicators for risk of hypertension include obesity, abdominal obesity and weight gain.

Anti-hypertension medications should be started if hypertension is diagnosed. But, with weight-loss, a significant fall in blood pressure may permit a decrease in the number of medications taken or decrease the amount of medication taken. Prevention would be better than any drug.

Given the important pathophysiologic links between weight and hypertension described, a significant increase in the prevalence of hypertension in coming years could be expected, if trends of increasing weight in the population are not stabilized and reversed.

Related Conferences: 5th  International Conference on Obesity & Weight Management, December 05-07, 2016, USA; 3rd International Conference on Health Informatics & Technology, June 27-29, 2016, USA; 6th Global Healthcare Summit, August 22-24, 2016, USA; Global Summit &  Expo on Healthcare, November 09-11, 2016, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; American Society of Hypertension 2016; British Hypertension Society  Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; European Hypertension Congress2016; International Conference on Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada

Track 3: Renal Hypertension

Renal hypertension, also called renovascular hypertension, is elevated blood pressure caused by kidney disease. It is a syndrome which consists of high blood pressure caused by the kidneys' hormonal response to narrowing of the arteries supplying the kidneys (renal artery stenosis). When functioning properly this hormonal axis regulates blood pressure. Due to low local blood flow, the kidneys mistakenly increase blood pressure of the entire circulatory system. It is a form of secondary hypertension a form of hypertension whose cause is identifiable. This session mainly accounts for the various causes and symptoms of renovascular hypertension, along with its pathogenesis, diagnosis and treatment.

High blood pressure is dangerous partly because the patients generally do not experience the symptoms, so organ damage can occur slowly without being recognized. Renal hypertension can cause chronic kidney disease. Various techniques have been developed to diagnose renal hypertension using digital image processing of radiographs. Medications are used first to try to control high blood pressure in renal hypertension. In some people with renal hypertension due to narrowing of the renal artery, even taking three or more medications every day may not adequately control blood pressure. In these situations, a procedure like angioplasty or stenting, to improve blood flow to the kidneys can often help.

Its prevalence is 2% in those who have a diastolic blood pressure of more than 100 mmHg and approximately 30% in patients who have diastolic blood pressure more than 130mmHg. Patients with renal hypertension are at increased risk of end organ dysfunction, including permanent kidney damage, if inadequate pharmacologic therapies are used to control blood pressure.

Related Conferences: 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA;  8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9thArrhythmia  Meeting, July 14-15 2016, Australia ; ASH Meeting  2016;  Ischemic Heart Diseases Conference, October 20-21, 2016  Chicago, USA; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; European Hypertension Congress 2016 ; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon;  British Hypertension Society 2016 ;  3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia

Track 4: Pulmonary Hypertension

Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, leading to shortness of breath, dizziness, fainting, leg swelling and other symptoms. Having pulmonary arterial hypertension (PAH) means that one has a high blood pressure in the arteries that go from the lungs to heart. Symptoms of pulmonary hypertension do not usually occur until the condition has progressed. The first symptom of pulmonary hypertension is usually shortness of breath with everyday activities, such as climbing stairs. Fatigue, dizziness, and fainting spells also can be symptoms. The molecular mechanism of pulmonary arterial hypertension (PAH) is not known yet, but it is believed that the endothelial dysfunction results in a decrease in the synthesis of endothelium-derived vasodilators such as nitric oxide and prostacyclin. Diagnosis of the severe heart condition includes mainly Echocardiography or as per the signs and symptoms of the condition.

The various related issues with Pulmonary Hypertension include HIV Associated Pulmonary HypertensionLiver Disease and Pulmonary Hypertension and PH in Association with Sickle Cell Disease

Idiopathic pulmonary arterial hypertension is a rare disease with an incidence of about 2-3 cases per million per year and a prevalence of about 15 per million. Adult females are almost three times more likely to be present with IPAH than adult males. The presentation of IPAH within children is more evenly split along gender lines. Up to 4% of people who suffer a pulmonary embolism go on to develop chronic thromboembolic disease including pulmonary hypertension. Levels of mortality are very high in pregnant women with severe pulmonary hypertension.

Related Conferences: 5th  International Conference on Obesity & Weight Management, December 05-07, 2016, USA; 3rd International Conference on Health Informatics & Technology, June 27-29, 2016, USA; 6th Global Healthcare Summit, August 22-24, 2016, USA; Global Summit &  Expo on Healthcare, November 09-11, 2016, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; American Society of Hypertension 2016; British Hypertension Society  Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; European Hypertension Congress2016; International Conference on Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada

Track 5: Hypertension in Pregnancy

Gestational hypertension or pregnancy-induced hypertension (PIH) is the development of new hypertension in a pregnant woman after 20 weeks gestation without the presence of protein in the urine or other signs of Pre-eclampsia in pregnancy. It is a temporary diagnosis for hypertensive pregnant women who do not meet criteria for preeclampsia or chronic hypertension (hypertension first detected before the 20th week of pregnancy). The diagnosis is changed to, Preeclampsia, if proteinuria or new signs of end-organ dysfunction develop and chronic (primary or secondary) hypertension, if blood pressure elevation persists ≥12 weeks postpartum.

The risk factors for Gestational hypertension comprise maternal causes like obesity, past history or adolescent pregnancy, multiple gestations, and family history. There is no specific treatment, but it is monitored closely to rapidly identify pre-eclampsia and its life-threatening complications. Drug treatment options are limited, as many antihypertensive drugs may negatively affect the foetus. During gestational hypertension a women must be offered an integrated package of care, covering admission to hospital, treatment, measurement of blood pressure, testing for proteinuria and blood tests.

Gestational hypertension in a future pregnancy ranges from about 1 in 8 (13%) pregnancies to about 1 in 2 (53%) pregnancies.

Related Conferences: 5th  International Conference on Obesity & Weight Management, December 05-07, 2016, USA; 3rd International Conference on Health Informatics & Technology, June 27-29, 2016, USA; 6th Global Healthcare Summit, August 22-24, 2016, USA; Global Summit &  Expo on Healthcare, November 09-11, 2016, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; American Society of Hypertension 2016; British Hypertension Society  Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; European Hypertension Congress2016; International Conference on Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada

Track 6: Hypertension Risk Factors

High Blood Pressure has many causative factors such as age, race, family history, obesity, not being physically active, consuming tobacco, too much salt (sodium) in diet, too little potassium and vitamin D in diet, drinking too much alcohol, stress and certain chronic conditionsThere are general risk factors that can be responsible for raising anyone's risk of hypertension. Although high blood pressure is most common in adults, children may be at risk, too. For some children, high blood pressure is caused by problems with the kidneys or heart. But for a growing number of kids, poor lifestyle habits, such as an unhealthy diet, obesity and lack of exercise, contribute to high blood pressure. Sometimes pregnancy contributes to high blood pressure, as well. Certain diseases and medications are specific causes of high blood pressure. 

Cardiovascular disease represents the leading cause of morbidity and mortality in Western countries, and hypertension-related cardiovascular events or hypertensive emergencies affect about 37 million people per year, worldwide. In this perspective, hypertensive patients are at increased risk to experience cardiovascular events during life-long period, and treatment of high blood pressure represents one of the most effective strategies to reduce global cardiovascular risk.

Related Conferences: 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA;  8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9thArrhythmia  Meeting, July 14-15 2016, Australia ; ASH Meeting  2016;  Ischemic Heart Diseases Conference, October 20-21, 2016  Chicago, USA; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; European Hypertension Congress 2016 ; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon;  British Hypertension Society 2016 ;  3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia

Track 7: Hypertension Diagnosis

Hypertension, or high blood pressure, is the leading risk factor associated with death in the world but is largely asymptomatic and often undetected in patients. Hypertension is typically asymptomatic and only detected through opportunistic screening. Symptoms only manifest when blood pressure reaches very high levels (usually >200 mmHg systolic), and can include headache, dizziness and nose bleeding. It is usually diagnosed when a patient’s blood pressure is repeatedly found to be 140/90 mmHg or higher in a clinical setting and average readings taken using ambulatory blood pressure monitoring or monitoring at home are higher than 135/85 mmHg. Once hypertension has been diagnosed, further tests should be conducted, including urine testing, blood tests, an eye examination and a 12-lead electrocardiogram (ECG).Primary hypertension, in which no specific cause is found, affects 95% of patients.

Blood pressure is expressed in terms of systolic blood pressure (higher reading), which reflects the blood pressure when the heart is contracted (systole), and diastolic blood pressure (lower reading), which reflects the blood pressure during relaxation (diastole). Hypertension can be diagnosed when either systolic pressure, diastolic pressure, or both are raised.

Blood pressure is determined by the cardiac output balanced against systemic vascular resistance. The process of maintaining blood pressure is complex, and involves numerous physiological mechanisms, including arterial baroreceptors, the renin–angiotensin–aldosterone system, atrial natriuretic peptide, endothelins, and mineralocorticoid and glucocorticoid steroids. 

Related Conferences: 5th  International Conference on Obesity & Weight Management, December 05-07, 2016, USA; 3rd International Conference on Health Informatics & Technology, June 27-29, 2016, USA; 6th Global Healthcare Summit, August 22-24, 2016, USA; Global Summit &  Expo on Healthcare, November 09-11, 2016, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; American Society of Hypertension 2016; British Hypertension Society  Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; European Hypertension Congress2016; International Conference on Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada

Track 8: Hypertensive Emergency

Complications of hypertension are clinical outcomes that result from persistent elevation of blood pressure. Hypertension is a risk factor for all clinical manifestations of atherosclerosis since it is a risk factor for atherosclerosis itself. It is an independent predisposing factor for heart failurecoronary artery disease,stroke, renal disease, and peripheral arterial disease. It is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries.

The various complications or manifestations arising due to high blood pressure include Hypertension RetinopathyPrimary Hypertension, Secondary Hypertension, Hypertensive Crisis, Gestational Hypertension, Ocular Hypertension and Epithelial Seizure in Children, Risk of Ischemic Heart Disease, Cognitive Impairment and Dementia, Hypertensive Nephropathy.

Uncontrolled high blood pressure can lead to different risk factors like heart attack or stroke, heart failure, aneurysm, weakened and narrowed blood vessels in kidneys, trouble with memory or understanding, thickened, narrowed or torn blood vessels in the eyes and metabolic syndrome.

Related Conferences: 5th  International Conference on Obesity & Weight Management, December 05-07, 2016, USA; 3rd International Conference on Health Informatics & Technology, June 27-29, 2016, USA; 6th Global Healthcare Summit, August 22-24, 2016, USA; Global Summit &  Expo on Healthcare, November 09-11, 2016, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; American Society of Hypertension 2016; British Hypertension Society  Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; European Hypertension Congress2016; International Conference on Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada

Track 9: Diet and Lifestyle in Hypertension management

High blood pressure, which is also called hypertension, increases the risk of developing many serious health problems, including heart disease, stroke, and kidney disease. Evaluation and Treatment of High Blood Pressure recommendations have defined “hypertension” as a BP of ≥140/90 mm Hg. The risk of cardiovascular diseases in patients with hypertension can be greatly reduced with effective antihypertensive therapy. 

Maintenance of normal body weight, following a proper diet plan, lifestyle modification including exercise, avoiding high-sodium content foods, limited alcohol consumption and appropriate medications as prescribed by the doctor may lead to a controlled and manageable blood pressure account. Also monitoring the blood pressure regularly may prevent hypertension and reduce the risk of high blood pressure-related health problems.

Related Conferences: 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA;  8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9thArrhythmia  Meeting, July 14-15 2016, Australia ; ASH Meeting  2016;  Ischemic Heart Diseases Conference, October 20-21, 2016  Chicago, USA; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; European Hypertension Congress 2016 ; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon;  British Hypertension Society 2016 ;  3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia

Track 10: Hypertension Epidemiology

Hypertension is a powerful risk factor for fatal and nonfatal cardiovascular disease events. Data from observational studies indicate that this risk is continuous, without evidence of a threshold, down to blood pressures as low as 115/75 mm Hg. Randomized controlled trials have convincingly shown that treatment of hypertension reduces the risk of stroke, coronary heart diseasecongestive heart failure, and mortality. Various studies of hypertension control have been performed in a variety of epidemiological and practice settings. 

Despite the recognition that diabetic persons are at especially high risk of cardiovascular disease, studies suggest that hypertension is as poorly controlled in diabetic persons as it is in non-diabetics. Chronic kidney disease represents another comorbidity associated with both difficult blood pressure control and high cardiovascular risk. Various patient characteristics have been associated with uncontrolled hypertension, including age, obesity, and lack of exercise. These characteristics are risk factors for hypertension itself and presumably contribute directly to difficult blood pressure control.

Related Conferences: 5th  International Conference on Obesity & Weight Management, December 05-07, 2016, USA; 3rd International Conference on Health Informatics & Technology, June 27-29, 2016, USA; 6th Global Healthcare Summit, August 22-24, 2016, USA; Global Summit &  Expo on Healthcare, November 09-11, 2016, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; American Society of Hypertension 2016; British Hypertension Society  Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; European Hypertension Congress2016; International Conference on Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada

Track 11: Advanced Treatment Approaches

Treating high blood pressure can take a multi-pronged approach including diet changes, medication, and exercise. Hypertension, or high blood pressure, is dangerous because it can lead to strokes, heart attacks, heart failure, or kidney disease. The goal of hypertension treatment is to lower high blood pressure and protect important organs, like the brain, heart, and kidneys from damage. Treatment for hypertension has been associated with reductions in stroke (reduced an average of 35%-40%), heart attack (20%-25%), and heart failure (more than 50%), according to research.

Because hypertension rarely causes specific symptoms, it is not identified until an individual’s blood pressure is measured by a physician or it causes a catastrophic complication such as stroke or heart attack. Accurate diagnosis by blood pressure measurement is essential. Many advanced treatment approaches and medications have been established for the treatment and management of hypertension that may describe this session.

Related Conferences: 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA;  8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9thArrhythmia  Meeting, July 14-15 2016, Australia ; ASH Meeting  2016;  Ischemic Heart Diseases Conference, October 20-21, 2016  Chicago, USA; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; European Hypertension Congress 2016 ; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon;  British Hypertension Society 2016 ;  3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia

Track 12: Clinical case reports

High blood pressure, also known as hypertension, affects millions -- even children and teens. It is a common condition that catches up with most people who live into older age. The exact cause of hypertension is unknown, but there are several factors and conditions that may contribute to its occurrence. About one in every four adults has hypertension.

High blood pressure is often called a "silent disease" because people usually don't know they have it; there may be no outward symptoms or a sign, so monitoring the blood pressure is critical. Treating high blood pressure can take a multi-pronged approach including diet changes, medication, and exercise. Hypertension treatment comes in many forms -- from lifestyle changes to medication.

Thus, case study on patients with different forms of Hypertension, may lead to a better way of improvement in emerging ideas or techniques for treating High Blood Pressure.

Related Conferences: 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA;  8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9thArrhythmia  Meeting, July 14-15 2016, Australia ; ASH Meeting  2016;  Ischemic Heart Diseases Conference, October 20-21, 2016  Chicago, USA; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; European Hypertension Congress 2016 ; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon;  British Hypertension Society 2016 ;  3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia

Conference Series LLC is glad to invite you to the “2nd International Conference on Hypertension & Healthcare” to be held during September 11-13, 2017 at Amsterdam, Netherlands. The conference emphasizes the theme “New insights in diagnosis and management for hypertension focusing on the latest ideas and advances for hypertension treatment and management. Hypertension 2017 event welcomes the innovative strategies in the area of hypertension research and also proposes a unique opportunity for the explorers from all over the world to gather, share and perceive new scientific interactions upon the various perceptions of hypertension.

Conference Series LLC organizes 600+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

For more details please visit: http://hypertension.conferenceseries.com/

Conference Highlights:

  • Hypertension
  • Hypertension & Obesity
  • Renal Hypertension
  • Pulmonary Hypertension
  • Gestational Hypertension 
  • Hypertension Risk Factors
  • Hypertension Diagnosis
  • Hypertensive Emergency
  • Hypertension Management
  • Hypertension Epidemiology
  • Advanced Treatment Approaches
  • Case Reports

Importance & Scope:

Hypertension is a major risk factor for cardiovascular diseases, cerebrovascular events and ischaemic heart diseases, so is therefore one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. It is often symptomless, so screening is vital before damage is done. Many surveys continue to show that hypertension remains underdiagnosed, undertreated and poorly controlled. Overall, the prevalence of hypertension (at least ≥140/90 mm Hg or on treatment) in those aged over 35 was observed to be 32% in men and 27% in women.

Blood Pressure has a skewed normal distribution within the population and the currently accepted model assumes risk is continuously related to BP. Essential hypertension (primary, cause unknown) accounts for the majority of cases, particularly in the older patient.

Hypertension 2017 is an international platform for presenting research about Hypertension and related concepts, sharing alternative ideas about the severe cardiovascular risk factor, thus contributing to the dissemination of information about the trouble for the welfare of the society.

Overall Prevalence of Hypertension Globally

 

Why Amsterdam:

Amsterdam is a good place for universities and cardiovascular research institutes like VU University Medical Canter, MRes Cardiovascular Research and more cardiology research centres with 3.6 percent of the GNP, Amsterdam makes the second highest investment in research and development in the country. About 61percent of R&D spending goes to the very pronounced publicly funded and university research landscape. Industry receives about a 27-percent share. Amsterdam is unique in that science as a resource is available to industrial companies in a highly compact manner and offers companies excellent cooperation opportunities.

Members Associated with Hypertension

There are 560 Cardiology Specialists near and 1000 Cardiology Specialists in Netherlands and 32, 000 Cardiology Specialists in worldwide.

Hospitals Associated with Hypertension

Amsterdam Hospitals

  • University Medical Center St. Radboud
  • Erasmus MC
  • University Medical Center Utrecht
  • Haven Hospital and Institute for Tropical Zietken
  • VU Medical Centre
  • Westeinde Hospital
  • University Medical Center St. Radboud

Netherlands Hospitals

  • St. Elizabeth’s Hospital
  • VU University Medical Center
  • Academic Medical Center
  • Medical Centre Alkmaar
  • St. Antonius Ziekenhuis Nieuwegein
  • St. Maarten Medical Center
  • Leiden University Medical Center
  • Ziekenhuis Amstelveen

   Globe:

  • American Cardiology and Nuclear Practice
  • AMG Cardiovascular Consultants
  • BehringHospital Vall D'Hebron, Laboratorio ecocardiografia, Barcelona
  • Calvert Cardiology Clinic
  • Cardio Care, LLC
  • Cardiology and Internal Medicine PA
  • Cardiology Center
  • Cardiovascular Center Of Hagerstown
  • Cardiovascular Diagnostic Center, PA
  • Columbia Cardiac Care
  • Coronary Artery Disease NSC "The M. D. Strazhesko Institute of Cardiology" Kiev
  • Delmarva Heart, LLC’
  • Doctors Community Hospital
  • Suburban Cardiology and Internal Medicine, PC
  • Taunton Satellite Office
  • The Cambridge Hospital
  • The Heart Center of Metro West
  • The Plymouth Heart Center
  • Tufts Medical Center
  • UMass Memorial Health Care Cardiac Ultrasound Laboratory
  • UMass Memorial Medical Health Care-Memorial Campus
  • West Roxbury Veterans Affairs Medical Center
  • Whidden Hospital
  • Winchester Cardiac Ultrasound
  • Winchester Hospital Echocardiography Laboratory
  • WPA-Woburn Medical

 

Societies Associated with Hypertension

Amsterdam

  • European society of cardiology

Netherlands

  • Netherlands Society Hypertension
  • Netherlands Society of Cardiology
  • Dutch Society of Cardiology
  • The British Society of Amsterdam and the Netherlands

Globe:

  • Arun dal heart associates
  • Cardiology Associates, LLC Annapolis
  • Cardiology Associates, LLC Kent Island
  • Cardiovascular Specialists of Frederick
  • Chesapeake and Washington Heart Care, PC
  • Chesapeake Cardiovascular Associates- Woodholme
  • Child Cardiology Associates
  • Delaware Cardiovascular Associates Elkton Office
  • Patuxent Cardiology Associates
  • Steward Medical Group, LLC
  • Steward Physician Network, Inc.
  • Suburban Cardiology and Internal Medicine, PC
  • The Cardiovascular Specialists

Universities Associated with Hypertension

 Amsterdam universities

  • University of Amsterdam
  • Academic Medical Center
  • VU University Amsterdam
  • Amsterdam University College
  • Amsterdam University of Applied Sciences
  • Vrije Universiteit Amsterdam
  • Webster University

Netherlands Universities

  • Heidelberg University
  • Pieter Nieuwland College
  • Bredero Beroepscollege
  • Utrecht University
  • University of Groningen
  • Radboud University Nijmegen
  • Wageningen University
  • Erasmus University Rotterdam
  • Tilburg University
  • Hogeschool van Amsterdam

Worldwide

  • Anglia Ruskin University
  • Arkansas Tech University
  • Canterbury Christ Church University
  • Colorado State University
  • Johns Hopkins University
  • Plymouth University
  • Stanford University
  • Swansea University
  • The University of Sydney
  • Ulster University
  • University of Leeds
  • University of Oxford

Industries Associated with Hypertension

Globe

  • Bausch + Lomb,
  • Bayer HealthCare Pharmaceuticals,
  • Berlin-Chemie, Biotronik,
  • opTec BerlinBrandenburg
  • Pfizer and Sanofi
  • OCEAN HEALTHCARE INDUSTRIES
  • CLINTON INDUSTRIES INC.

Global Market at a Glimpse:

High blood pressure or hypertension is the most important risk factor for cardiovascular disease.In over 90% of cases there may be no identifiable cause of hypertension, in which case the condition is known as essential hypertension. The remaining 10% of cases, hypertension may be secondary in nature as a consequence of another medical problem, such as kidney disorders, adrenal tumours, or some drugs. The prevalence of hypertension is forecasted to grow from 234 million in 2010 to 246 million in 2016 across the seven major markets (France, Germany, Italy, Spain, UK, US, and Japan). In 2016, the US is still expected to be the largest market for hypertension, with an anticipated 83 million sufferers, followed by Japan at 49 million. According to the International Society of Hypertension, there is a clear recognition of hypertension as a major public health issue across all the 7MM. The global cardiovascular market recorded a sale of $170bn in the year 2010 and is set to grow to $187bn in 2016 at a CAGR of 1.6%. The US continued to be the largest market, with a share of 40% of the overall market. Anti hypertensives remained the largest drug class in the year 2010, with a global sale of $37.6bn and a global market share of 22%. The global market for hypertension management devices is a variable and dynamic market that will experience a strong growth through the year 2023 as an increasing number of devices would become available to address a largely unmet clinical needs.

 

Products manufactured by the industry related Hypertension

  • My Lab™ Gamma’-
  • Multipurpose ultrasound imaging smart portable ultrasound system
  • Ultrasound transducer
  • Micro convex ultrasound
  • Pencil probe ultrasound
  • Transesophageal ultrasound transducer
  • FUJIFILM Medical Systems U.S.A., Inc.- latest version of Synapse Cardiovascular 6.0* and
  • Synapse 3D
  • HAUSMANN INDUSTRIES, INC.-Echo-Scan
  • Kontron

Kontron's Medical Computers enable sustainable and viable medical solutions for several applications.          

Fund Allotment to Hypertension Research:

The NIH (National Institute of Health) Funding Opportunity Announcement (FOA), funded by the Patient-Centered Outcomes Research Institute (PCORI), funds up to two new patient-centred comparative effectiveness clinical trials, with the goal of comparing alternative, evidence-based ways to reduce inadequate control of hypertension and disparities in outcomes among high-risk populations, including racial/ethnic minority groups, patients with low socioeconomic status (SES), and individuals residing in rural geographical areas with an above average lifetime risk of cardiovascular disease (CVD). This initiative is supported by the Hypertension Disparities Reduction Program Partnership (HDRPP), a research partnership between NHLBI, NINDS and PCORI, with funds provided by PCORI to the NIH.

The fund allotment granted by the NIH is raised up to $21,500,000 worldwide for supporting research works associated with the advances in treatment and management of Hypertension

Statistics of Physicians, Researchers and Academicians working on Hypertension:

The estimated statistics of the number of physicians, academicians and researchers working upon the advancement in the treatment and management of hypertension are as described in the pie chart here in.

 

Hypertension 2016

We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making Hypertension 2016 a wonderful event!

Thank you for participating in the International Conference on Hypertension & Healthcare (Hypertension-2016).

It was a great pleasure seeing many familiar faces, several new ones, and many others who have just joined the Hypertension-2016 at the Holiday Inn Toronto International Airport, Canada.

We hope you had a remarkable time at the conference.

Thank you to all the Honorable Guests, Keynote Speakers, Moderator, Chairs, Co-Chairs, Speakers, Students and Delegates, the Organizing Committee and Editorial Board members for their support. The conference would not have been the same without each one of you.
We enjoyed hosting the event and hope you walked away with new ideas, inspiration and ambition to promote work in all possible ways.

Conference series LLC played host to a diverse panel of key members of the Hypertension community from research lab, industry, academia and financial investment practices, discussing the future of Hypertension specialties. This event was really aimed for examining where the real Hypertension specialties are going in the future and purpose of the event was to provide an opportunity for cross fertilization of ideas and development of ideas, in the field of Hypertension.

Focusing on Hypertension & Obesity, Hypertension Risk factors, Hypertension Diagnosis, Gestational Hypertension, Hypertension Management, Case Reports & Hypertension Epidemiology as well, the two days of discussions enabled professionals to gain an insight into the current innovations and opened up networking opportunities.

Hypertension-2016 Organizing Committee would like to thank the Moderators of the conference, Ms. Hatice Y. Foell, USA , who contributed a lot for the smooth functioning of this event.

The highlights of the meeting were the eponymous lectures, delivered by Pavel Hamet from University of Montreal, Canada , Naranjan S Dhalla, University of Manitoba, Canada , Pollen K F Yeung , Dalhousie University, Canada, Robert S Fitzgerald, Johns Hopkins University, USA, These talks were of great interest to the general cardiologists and were enormously informative.

Conference series LLC International Conference on Hypertension & Healthcare was a great success with the support of international, multi professional steering committee and coordinated by the Journal of Clinical & Experimental Cardiology, Journal of Hypertension: Open Access , Journal of Cardiovascular Diseases & Diagnosis and Cardiovascular Pharmacology: Open Access.


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date September 11-13, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations